Comparison of serum cytokeratin-18, CEA and CA 19-9 levels in esophageal and gastric cancers

Eastern Journal of Medicine

Volumn 9, Issue 2, 2004, Pages 72-78

  Tuncer, Ilyas ^a   Dülger, Haluk ^a   Uygan, Ismail ^a   Öztürk, Mustafa ^a   Kotan, Çetin ^a   Şekeroǧlu, Ramazan ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

CA19 9; CEA; Cytokeratin 18; Esophageal carcinoma; Gastric carcinoma

Indexed keywords

EID: 76349099591     PISSN: 13010883     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol 1994; 21: 403-10.
2. Coombes RC, Powels TJ. Tumour markers in the management of human cancer. In: Deeley TJ, editor. Topical Reviews in Radiotherapy and Oncology. Bristol: Wright PGS, 1982:39.
3. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218: 583-92.
4. Day NE, Varghese C. Oesophageal cancer. Cancer surv 1994; 20:43-54.
5. Mandorwski S, Lourenco LG, Forones NM. CA72-4 and CEA in serum and peritoneal washing in gastric cancer. Arq Gastroenterol 2002; 39:17-21.
6. Kornek G, Schenk T, Raderer M, Djavarnmad M, Scheithauer W. Tissue polypeptide specific antigen in monitoring palliative treatment response of patients with gastrointestinal tumours. Br J Cancer 1995; 71: 182-5.
7. Lopez JB, Royan GP, Lakhwani MN, Mahadaven M, Timor J. CA72-4 compared with CEA and CA19-9 as a marker of some gastrointestinal malignancies. Int J Biol Markers 1999; 14: 172-7.
8. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA19-9 and CA72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002; 22: 2311-6.
9. Horie Y, Miura K, Matsui K. Marked elevation of plasma carcinoembriyonic antigen and stomach carcinoma. Cancer 1996; 77: 1991-7.
10. Kodera Y, Yamamura Y, Torii A, et al. The prognostic value of preoperative serum levels of CEA and CA19-9 in patient with gastric cancer. Am J Gastroenterol 1996; 91: 49-53.
11. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31:11-24.
12. Tschentscher P, Wagenera C, Neumaier M. Sensitive and specific cytokeratin 18 reverse transcription-polymerase chain reaction that excludes amplification of processed pseudogenes from contaminating genomic DNA. Clinical Chemistry. 1997; 43: 2244-50.
13. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Pentilla I, Alhava E. Clinical value of serum tumour markers CEA, CA50, and CA242 in distinction between malignant versus benign disease causing jaundice and cholestasis; results from a prospective study. Anticancer Res1992; 12: 1689-94.
14. Bunn PA, Cohen MI, Widerlite L, Nugent JL, Matthews MJ, Minna JD. Simultaneus and plasma immunoreactive CEA in 108 patients undergoing gastroscopy. Gastroenterology 1979; 76: 734-41.
15. Ridlander L, Zeigler E, Bergman T, et al. Molecular characterization of a tissue-polipeptidespecific-antigen epitop and its relationship to human cytokeratin 18. Eur J Biochem 1996; 241: 309-15.
16. Moll R. Cytokeratins in histological diagnosis of malignant tumors. Int J Biol Markers 1994; 912: 63-9.
17. 17- Sudstom BE, Stigbrant TI. Cytokeratins and tissu polipeptide antigen. nt J Biol Markers 1994; 9: 102-8.
18. Bonfrer JM, Groeneveld EM, Korse CM, van Dalen A, Oomen LC, Ivanyi D. Monoclonal antibody M3 used in TPSTM assay for the quantification of TPA recognizes keratin 18. Tumor Biol 1994; 15: 210-22.
19. Lam KY, Loke SL, Shen XC, Ma LT. Cytokeratin expression in non-neoplastic oesophageal epithelium and squamous cell carcinoma of the oesophagus. Virchows Arch 1995; 426:345-9.
20. Staab HJ, Anderer FA, Brummendorf T, Fisher R. Prognostic significance of preoperative carcinoembryonic antigen in stomach and colorectal cancer. Cancer Detect Prev 1983; 6: 149-53.
21. Victorzon M, Haglund C, Lundin J, Roberts PJ. A prognostic value of CA19-9 but not of CEA in patients with gastric cancer. Eur J Surg Oncol 1995; 21: 379-84.
22. Ial'chenko NA, Lagutin VD, Lavik NN, Musin II. The clinica information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum. Vopr Onkol 1991; 37: 921-4.
23. Gion M, Tremolada C, Mione R, della Palma P, Dittadi R, Zari C, Nosadini A, et al. Tumor markers in serum of patients with primary squamous cell carcinoma of the esophagus. Tumor 1989; 75: 489-93.
24. Tachibana M, Takemoto Y, Nakashima Y, Kinugasa S, Kotoh T, Dhar DK, at al. Serum carcinoembryonic antigen as a prognostic factor in resectable gastric cancer. J Am Coll Surg 1998; 187: 64-8.
25. Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 2000;16: 105-10.
26. Koga T, Kano T, Souda K, Oka N, Inokuchi K, et al. The clinical usefulness of preoperative CEA determination in gastric cancer. Jpn J Surg 1987; 17: 342-7.
27. Bates SE, Longo DE. Use of serum tumor markers in cancer diagnosis and management. Semin Oncol 1987; 14: 102-138.
28. Berg el, Robinson MK, Manson O, et al. A carbohydrate domain common to both sialyl Le a and sialyl lex is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1: J Biol Chem1991; 66: 1486-7.
29. Yoshikawa T, Nishida K, Tanigawa M, Fukumoto K, Kondo M. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies. Digestion 1985; 31; 67-76.
30. Ker CG, Chen Js, Lee KT, Shee PC, Wu CC. Assesment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J Gastro Hepatol 1991; 6: 505-8.
31. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC Sci Publ 1993; 121: 806.
32. Marrelli D, Roviello F, De Stefano A, Farnetani M, Garosi L, Messano A, Pinto E. Prognostic significance of CEA, CA19-9 and CA72-4 preoperative serum levels in gastric carcinoma. Oncology 1999; 57: 55-62.
33. Fabris C, Bosso D, Meggiato T, Del Favero G, Piccoli A, Fogar P, et al. Different role of liver dysfunction and damage in increasing serum CA19-9, TPA and CEA in patients with pancreatic carcinoma. Int J Pancreatol 1990; 6: 1-8.
34. Patai A, Heber S, Dobronte Z, Kovacs LG. Diagnostic value of CA 19-9 and CEA in gastrointestinal pathology. Orv Hetil 1992; 133:1301-7.